Impact of surgical staging in stage I clear cell XXXX .

@entity1 @entity32644 @entity420 @entity1349 @entity15539
AIM: The aim of this study was to evaluate the impact of surgical staging in stage I clear cell @entity420 (CCC). METHODS: We performed a retrospective review of 165 @entity1 with stage I CCC treated with optimal or nonoptimal staging surgery. RESULTS: The median follow-up period in this study was 67 months. No significant difference was detected in @entity1349 ( @entity1349 ) or @entity1349 ( @entity1349 ) between @entity1 optimally and nonoptimally staged ( @entity1349 : P = 0.434; @entity1349 : P = 0.759). The estimated 5-year @entity1349 and @entity1349 rates were 92.1% and 95.3% in @entity1 with stages IA/ @entity32644 and 81.0% and 83.7% in stages @entity15539 /IC3, respectively. The multivariate analysis indicated that stages @entity15539 /IC3 predicted worse @entity1349 and @entity1349 than stages IA/ @entity32644 in stage I CCC @entity1 ( @entity1349 : P = 0.011; @entity1349 : P = 0.011). Subsequently, we investigated the impact of surgical staging, respectively, in stages IA/ @entity32644 and stages @entity15539 /IC3. Significant differences were observed in PFS and @entity1349 between @entity1 optimally and nonoptimally staged with stages IA/ @entity32644 ( @entity1349 : P = 0.021; @entity1349 : P = 0.024), but no significant difference was found in those with stages @entity15539 /IC3. The multivariate analysis indicated that nonoptimal staging surgery predicted worse @entity1349 than the optimal staging surgery in stages IA/ @entity32644 CCC @entity1 (P = 0.033). In addition, we investigated the impact of surgical staging for stages IA/ @entity32644 in the adjuvant chemotherapy group. The 5-year @entity1349 and @entity1349 rates in @entity1 optimally and nonoptimally staged with stages IA/ @entity32644 in the adjuvant chemotherapy group were 97.8% and 100%, and 85.2% and 89.4%, respectively. The multivariate analysis indicated that nonoptimal staging surgery predicted worse @entity1349 than the optimal staging surgery for stages IA/ @entity32644 @entity1 in the adjuvant chemotherapy group (P = 0.019). CONCLUSIONS: The prognosis for @entity1 with stage 1A/ @entity32644 is very good. Surgical staging category was the only independent prognostic factor for @entity1349 in stages IA/ @entity32644 CCC.
